StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q3 2026
5.4%
Period ended Sep 30, 2026
Change on a year earlier
-1.2 pts
6.6% in Q3 2025
History
44 quarters
Since Q4 2015
Sources
44
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%) (%)Year on yearSource
Q3 2026Sep 30, 20265.4%-1.2 ptsSEC Filing (0001628280-26-066601) ↗
Q2 2026Jun 30, 20266.1%+1.6 ptsSEC Filing (0001628280-26-048377) ↗
Q1 2026Mar 31, 20269.5%+6.5 ptsSEC Filing (0001628280-26-025365) ↗
Q4 2025Dec 31, 20258.0%+0.9 ptsSEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 20256.6%+2.7 ptsSEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 20254.5%+3.2 ptsSEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 20253.0%-8.7 ptsSEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 20247.1%-4.9 ptsSEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20243.9%-7.0 ptsSEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 20241.3%-8.0 ptsSEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 202411.7%+11.9 ptsSEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 202312.0%+22.8 ptsSEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 202310.9%+16.9 ptsSEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 20239.3%+15.4 ptsSEC Filing (0001628280-23-025156) ↗
Q1 2023Mar 31, 2023-0.2%+2.4 ptsSEC Filing (0001628280-23-012020) ↗
Q4 2022Dec 31, 2022-10.8%-23.2 ptsSEC Filing (0001628280-23-001516) ↗

Cite this data

StockData. (2026). Abbott Laboratories Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%) (%), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-vasc-yoy-rep

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.